SCHEMBL1629115

SCHEMBL1629115

CCCN(C)S(=O)(=O)c1cc(-c2ccnn2-c2ccccc2Cl)c(O)cc1O

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 7/20 0.51
NR3C2 P08235 1/20 0.38
PDE11A Q9HCR9 1/20 0.37
ESR1 P03372 5/20 0.36
MAPK14 Q16539 1/20 0.33
CYP2C8 P10632 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C18 P33260 2/20 0.33
FPR1 P21462 1/20 0.33
CYP2C19 P33261 1/20 0.33
PDE4B Q07343 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1628916 0.94 HSP90AA1 (0.49) HSP90AA1NR3C2PDE11AESR1MAPK14
SCHEMBL1629130 0.92 HSP90AA1 (0.49) HSP90AA1NR3C2PDE11AESR1MAPK14
SCHEMBL1629206 0.92 HSP90AA1 (0.51) HSP90AA1NR3C2PDE11AMAPK14FPR1
SCHEMBL1630390 0.89 HSP90AA1 (0.58) HSP90AA1NR3C2PDE11AESR1CYP2C8
SCHEMBL1630250 0.89 HSP90AA1 (0.46) HSP90AA1NR3C2PDE11AMAPK14
SCHEMBL1628882 0.88 HSP90AA1 (0.62) HSP90AA1NR3C2PDE11AESR1MAPK14
SCHEMBL1629715 0.88 HSP90AA1 (0.52) HSP90AA1NR3C2PDE11AMAPK14
SCHEMBL1216341 0.87 HSP90AA1 (0.48) HSP90AA1NR3C2
SCHEMBL1217338 0.87 HSP90AA1 (0.51) HSP90AA1NR3C2PDE11AMAPK14
SCHEMBL1629701 0.87 HSP90AA1 (0.52) HSP90AA1NR3C2PDE11ACYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776346-B1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2013-06-26 EP claimed
US-7932401-B2 Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant MERCK PATENT GMBH (DE) 2011-04-26 US claimed
US-20080085904-A1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2008-04-10 US claimed
EP-1776346-B1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2013-06-26 EP disclosed
US-7932401-B2 Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant MERCK PATENT GMBH (DE) 2011-04-26 US disclosed
US-20080085904-A1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085904-A1 1,5-Diphenylpyrazoles HSP90AB1, HSP90AA1, HSP90AB2P HSP90AA1 2/4885NR3C2 558/4885PDE11A 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.